- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03143946
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
Towards Optimal Personalized Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective:
This study aims to investigate if the proportion of NET patients with normal vitamin values can be increased, with vitamin suppletion and a personalized diet.
Methods:
This is a single center 18-week open-label, non-comparative, single-arm, intervention study. After inclusion and the first measurements, adult patients with metastasized or irresectable NET will continue with four weeks of standard treatment. After these four weeks participants with vitamin values below normal will get vitamin suppletion for each deficient vitamin and all participants will get the dietary intervention during 14 weeks. Effects of the intervention will be evaluated by quantitative analysis of blood and urine and questionnaires. The measurements, including; baseline characteristics, quantitative analysis of blood and urine and questionnaires will be performed at baseline (t=0), after 4 weeks (t=4) and after 18 weeks at end of study (t=18). Furthermore at t=18 a semi-qualitative interview will be performed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9713 GZ
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged ≥ 18 years
- NET-patients with serotonin producing or non-serotonin producing tumors, with gastro-intestinal, pancreatic, bronchopulmonary or unknown primary tumor site and with metastasized or irresectable disease
- Ability to comprehend Dutch (both reading and writing).
- Written informed consent provided.
- Use of somatostatin analogue for > 6 months.
Exclusion Criteria:
- Estimated life expectancy less than 6 months.
- Patients who have a history of another primary malignancy, except for radical and adequately treated malignancies from which the patient has been disease free for ≥ 1 year.
- Major abdominal surgery during study period.
- Patients already participated in the DIVIT-pilot study
- Known hypersensitivity of (components of) somatostatin analogue
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin supplement and diet advice
Single arm.
Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
|
Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change in the proportion of patients with normal vitamin values
Time Frame: 18 weeks
|
the change in the proportion of patients with normal vitamin values measured with quantitative analysis of blood and urine
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
nutrition state
Time Frame: 18 weeks
|
As measured with the total score with Patient-Generated Subjective Global Assessment (PG/SGA).
|
18 weeks
|
distress
Time Frame: 18 weeks
|
measured by the distress thermometer and problem list
|
18 weeks
|
problems
Time Frame: 18 weeks
|
as measured with the problem list.(the
mean of each item)
|
18 weeks
|
change in quality of life
Time Frame: 18 weeks
|
determined by the QLQ-GINET21 (a NET-specific EORTC quality of life questionnaire) and the cancer-specific EORTC QLQ-C30,
|
18 weeks
|
difference in the self-reported healthy eating pattern.
Time Frame: 18 weeks
|
as measured with a self-constructed scale
|
18 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201600626
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumor
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2United States, Canada
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Digestive System Neuroendocrine Tumor G1 | Metastatic Carcinoid Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Regional Digestive System Neuroendocrine Tumor G1 | Midgut Neuroendocrine Tumor G1 | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine Tumor | Neuroendocrine...Canada, United States
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2United States
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's HospitalCompletedNeuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine TumorUnited States
-
Dana-Farber Cancer InstituteBayer; NovartisCompletedNeuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine TumorUnited States
-
University of WashingtonEli Lilly and CompanyRecruitingLocally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Metastatic Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Digestive System Neuroendocrine Tumor | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine... and other conditionsUnited States
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
Clinical Trials on Vitamin supplement;
-
Physicians Committee for Responsible MedicineCompleted
-
Alcon ResearchCompleted
-
National and Kapodistrian University of AthensNational Hellenic Research FoundationCompletedOsteopenia | Postmenopausal OsteopeniaGreece
-
Physicians Committee for Responsible MedicineCompleted
-
University GhentFlemish Interuniversity Council (VLIR); Arba Minch University, EthiopiaCompletedVitamin A Deficiency | Anemia, Iron Deficiency | Cognitive Development | Helminthic InfectionEthiopia
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteRecruitingFrailty | Multiple Chronic Conditions | Weakness, MuscleUnited States
-
Mothaffar RimawiTerminated
-
Supplement Formulators, Inc.CompletedIncrease in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)United States
-
RWTH Aachen UniversityCompleted
-
Universiti Sains MalaysiaGold Choice Food Industries Sdn. BhdCompletedMetabolic SyndromeMalaysia